Targeting known mutations in cancer-related genes

Fixed and custom panels for cost-effective sequencing and easier data analysis

Targeted Cancer Sequencing

Targeted cancer sequencing focuses on a select set of genes, gene regions, or amplicons that have known associations with cancer. You can use fixed panels that contain cancer-associated genes or design custom panels based on genes of interest.

Next-generation sequencing (NGS) enables massively parallel sequencing of multiple genes and samples at one time. This high-throughput method offers distinct advantages over traditional capillary electrophoresis, including increased scalability, speed, and resolution.1,2 By performing targeted cancer sequencing with a focused gene panel, you can reduce costs and complete studies more quickly.

Focused panels for targeted cancer sequencing significantly narrow the scope of a sequencing project, reducing cost and data analysis burdens. Because it assesses a limited set of genes, targeted cancer sequencing allows for deeper coverage of those genes and higher sensitivity to call variants in rare tumor subclones confidently.

Learn More

Fixed panels offer the reassurance of expertly designed and analytically validated genomic content, focusing on genes with established cancer associations. This enables the highest sensitivity for rare variant calling in all sample types, including formalin-fixed, paraffin-embedded (FFPE) tissue.

Access PDF

With custom panels for targeted cancer sequencing, researchers can sequence hundreds of genomic regions of interest in a single panel. Gene content can be completely customized based on study objectives. Custom assays are compatible with various sample types, including FFPE tumors.

Learn More

Illumina offers several library preparation, sequencing, and data analysis options for cancer whole-genome sequencing. Streamlined library prep workflows and flexible kit configurations accommodate multiple study designs. Illumina systems deliver industry-leading data quality—in fact, approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.

Push-button apps in BaseSpace Sequence Hub simplify data analysis, so you can spend less time analyzing data and more time focusing on the next breakthrough.

Click on the below to view products for each workflow step.


An easy-to-use online software tool that provides dynamic feedback to optimize designs.

TruSight Cancer Sequencing Panel

A fixed panel containing 94 genes and 284 SNPs associated with cancer predisposition.

TruSight Tumor 15

Focused panel to assess relevant solid tumor somatic variants in a simple, sample-to-data workflow.

TruSight Myeloid Sequencing Panel

A fixed panel targeting oncogenic exons and tumor suppressor genes for myeloid malignancies.

TruSeq Amplicon - Cancer Panel

A fixed panel of somatic mutational hotspots in a broad spectrum of cancers.

TruSeq Custom Amplicon v1.5

A fully customizable assay for high plexity pools, and long tiling applications.

TruSight RNA Pan-Cancer

Targeting 1385 cancer-associated genes for gene expression, variant and fusion detection in all Oncology sample types including FFPE.

TruSeq Custom Amplicon Low Input

A fully customizable assay for low-input and formalin-fixed, paraffin-embedded (FFPE) DNA samples.

Nextera Rapid Capture Custom Enrichment Kit

Customized probe design to target 0.5–25 Mb of custom content.

MiniSeq System

Simplest and most affordable solution for low-throughput targeted cancer sequencing.

MiSeq System

Desktop sequencer featuring a simple NGS workflow, integrated data analysis software, and unmatched accuracy.

MiSeqDx Instrument

FDA-cleared in vitro diagnostic NGS system that also operates in research mode to generate accurate, reliable data.

NextSeq Series

Flexible desktop sequencers that support multiple applications.

MiSeq Reporter

Easy-to-use software for analysis and variant calling on the MiSeq System.

VariantStudio Software

A powerful analysis and reporting tool that provides biological insight into genomic variant data.

BaseSpace Sequence Hub

The Illumina genomics computing environment for NGS data analysis and management.

Local Run Manager

Easy-to-use software for automated on-instrument data analysis.

NGS in Clinical Research

Kenneth Bloom, MD, FCAP, Chief Medical Officer at Clarient (GE Healthcare) discusses the practical aspects of applying NGS in clinical research.

View Video
Detection of Actionable Alterations in Tumors
Detection of Actionable Alterations in Tumors

Wagle et al. demonstrate detection of genomic alterations in tumor samples by high-throughput targeted cancer sequencing.

Read Paper
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up
How NGS is Changing Tumor Analysis

Dr. Andrew Fellowes shares how his team uses NGS to analyze tumors for a wide range of mutations.

View Video
NGS Technologies Fuel Cancer Research
NGS Technologies Fuel Cancer Research

Endocrinologists use MiSeq System and TruSeq Custom Amplicon Assay to discover causative variants of heritable endocrine cancer.

Read Interview
NGS to Detect Blood Cancers
NGS to Detect Blood Cancers

Targeted NGS can identify myeloid-related genes with greater sensitivity than Sanger sequencing or cytogenetic methods.

Read Interview
  1. Ross MG, Russ C, Costello M, et al. Characterizing and measuring bias in sequence data. Genome Biol. 2013;14:R51.
  2. Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol. 2012;2012:251364.